NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved ...
MYCAPSSA is indicated for long-term maintenance treatment in acromegalypatients who haveresponded to and tolerated treatment with octreotide or lanreotide Conference call and webcast scheduled today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results